Comparison of Post PCI TIMI Flow Between Diabetic and Non-Diabetic Individuals
Article Sidebar
Main Article Content
Abstract
Background: Cardiovascular diseases remain the leading cause of morbidity and mortality globally, with diabetes significantly exacerbating the incidence and severity of coronary artery disease. Diabetic patients experience altered coronary blood flow dynamics, which can impact the efficacy of therapeutic interventions like percutaneous coronary intervention (PCI).
Objective: This study aims to compare the post-PCI Thrombolysis in Myocardial Infarction (TIMI) flow grades between diabetic and non-diabetic patients to assess the impact of diabetes on the short-term outcomes of coronary revascularization.
Methods: A retrospective observational study was conducted at the National Institute of Cardiovascular Diseases in Karachi, involving 3,000 patients who underwent primary PCI between January 2018 and December 2020. Patients were categorized into diabetic (1,500) and non-diabetic (1,500) groups. Data collected included demographics, coronary artery risk factors, TIMI flow grades before and after PCI, and the use of GPIIb/IIIa inhibitors. Statistical analysis was performed using SPSS version 25, employing chi-square tests, t-tests, and Mann-Whitney U tests for comparative analysis, with a p-value of <0.05 considered statistically significant.
Results: The study found significant differences in postoperative TIMI3 flow rates, with non-diabetic patients achieving a higher rate of TIMI3 (59.4%) compared to diabetic patients (58.1%). The use of GPIIb/IIIa inhibitors was higher in diabetic patients (34.7%) than in non-diabetic patients (1.8%). Additionally, diabetic patients showed a higher incidence of multi-vessel disease and more severe lesion profiles, including higher rates of triple branch lesions (45.9% vs. 39.9%) and left main lesions (53% vs. 43.9%).
Conclusion: Diabetic patients exhibit worse post-PCI TIMI flow grades and more complex coronary lesions compared to non-diabetic patients, suggesting that diabetes adversely affects the outcomes of coronary revascularization. These findings underscore the need for tailored therapeutic approaches to improve PCI outcomes in diabetic patients.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Zubair F, Nawaz SK, Nawaz A, Nangyal H, Amjad N, Khan MS. Prevalence of Cardiovascular Diseases in Punjab, Pakistan: A Cross-Sectional Study. J Public Health. 2018 Oct;26:523-9.
Roth GA, Mensah GA, Fuster V. The Global Burden of Cardiovascular Diseases and Risks: A Compass for Global Action. J Am Coll Cardiol. 2020 Dec 22;76(25):2980-1.
La Sala L, Pontiroli AE. Prevention of Diabetes and Cardiovascular Disease in Obesity. Int J Mol Sci. 2020 Oct 31;21(21):8178.
Figulla HR, Lauten A, Maier LS, Sechtem U, Silber S, Thiele H. Percutaneous Coronary Intervention in Stable Coronary Heart Disease—Is Less More? Deutsches Ärzteblatt Int. 2020 Feb;117(9):137.
Zheng W, Huang X, Zhao X, Gong W, Wang X, Nie S. Impact of stress hyperglycemia on the timing of complete revascularization in non-diabetes patients with ST elevation myocardial infarction and multivessel disease. Angiology. 2023 Jul;74(6):587-95.
Savić L, Mrdovic I, Asanin M, Stankovic S, Lasica R, Krljanac G, Simic D, Matic D. Prognostic Impact of Stress Hyperglycemia in Non-Diabetic Patients Treated with Successful Primary Percutaneous Coronary Intervention.
Mitsis A, Gragnano F. Myocardial Infarction With and Without ST-Segment Elevation: A Contemporary Reappraisal of Similarities and Differences. Curr Cardiol Rev. 2021 Jul 7;17(4).
Thrane PG, Kristensen SD, Olesen KK, Mortensen LS, Bøtker HE, Thuesen L, Hansen HS, Abildgaard U, Engstrøm T, Andersen HR, Maeng M. 16-Year Follow-Up of the Danish Acute Myocardial Infarction 2 (DANAMI-2) Trial: Primary Percutaneous Coronary Intervention vs. Fibrinolysis in ST-Segment Elevation Myocardial Infarction. Eur Heart J. 2020 Feb 14;41(7):847-54.
Elsanan MA, Tahoon IH, Mohamed GI, El-Dosouky II, Shehata IE. Predictors of non-obstructive coronary slow flow in poorly controlled type 2 diabetes mellitus: a cross-sectional study. BMC Cardiovascular Disorders. 2024 Feb 1;24(1):83.
Khan SQ, Ludman PF. Percutaneous Coronary Intervention. Medicine. 2022 Jul 1;50(7):437-44.
Bruning RS, Sturek M. Benefits of Exercise Training on Coronary Blood Flow in Coronary Artery Disease Patients. Prog Cardiovasc Dis. 2015 Mar 1;57(5):443-53.
Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C, Jørgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P. Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005 Apr 1;26(8):804-47.
Al Ali L, Groot HE, Assa S, Lipsic E, Hummel YM, van Veldhuisen DJ, Voors AA, van der Horst IC, Lam CS, van der Harst P. Predictors of adverse diastolic remodeling in non-diabetic patients presenting with ST-elevation myocardial infarction. BMC Cardiovascular Disorders. 2023 Jan 23;23(1):44.
Arnold SV, Bhatt DL, Barsness GW, Beatty AL, Deedwania PC, Inzucchi SE, Kosiborod M, Leiter LA, Lipska KJ, Newman JD, Welty FK. Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. Circulation. 2020 May 12;141(19):e779-806.
Liu HL, Liu Y, Hao ZX, Geng GY, Zhang ZF, Jing SB, Ba N, Guo W. Comparison of Primary Coronary Percutaneous Coronary Intervention Between Diabetic Men and Women With Acute Myocardial Infarction. Pak J Med Sci. 2015 Mar;31(2):420.
Fu R, Cui K, Yang J, Xu H, Yin D, Song W, Wang H, Zhu C, Feng L, Wang Z, Wang Q. Fasting Stress Hyperglycemia Ratio and In-Hospital Mortality After Acute Myocardial Infarction in Patients With Different Glucose Metabolism Status: Results From China Acute Myocardial Infarction Registry. Diabetes Res Clin Pract. 2023 Feb 1;196:110241.
Zhang J, Zeng P, Li R, Fan Z, Huang R, Cai X, Shao L, Liu F, Lei Y, Li D, Jin X. The Relationship between Admission Blood Glucose Levels and Major Adverse Cardiovascular Events during Hospitalization in Non-Diabetic ST-Segment Elevation Myocardial Infarction (Killip I) Patients Undergoing Primary Percutaneous Coronary Intervention.
Fathima SN. An Update on Myocardial Infarction. Curr Res Trends Med Sci Technol. 2021;1.
Kültürsay B, Yılmaz C, Güven B, Mutlu D, Karagöz A. Potential renoprotective effect of SGLT2 inhibitors against contrast-induced AKI in diabetic STEMI patients undergoing primary PCI. Polish Heart Journal (Kardiologia Polska). 2024;82(1):29-36.
Blöndal M, Ainla T, Eha J, Lõiveke P, Marandi T, Saar A, Veldre G, Edfors R, Lewinter C, Jernberg T, Jortveit J. Comparison of Management and Outcomes of ST-Segment Elevation Myocardial Infarction Patients in Estonia, Hungary, Norway, and Sweden According to National Ongoing Registries. Eur Heart J-Qual Care Clin Outcomes. 2022 May.